Significant antitumor activity of oncolytic adenovirus expressing human interferon-β for hepatocellular carcinoma

Journal of Gene Medicine

Volumn 10, Issue 9, 2008, Pages 983-992

  He, Ling Feng ^a   Gu, Jin Fa ^a   Tang, Wen Hao ^c   Fan, Jun Kai ^a   Wei, Na ^a   Zou, Wei Guo ^a   Zhang, Yan Hong ^a   Zhao, Li Li ^a   Liu, Xin Yuan ^a,b  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b ZHEJIANG SCI TECH UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Interferon ; Oncolytic adenovirus; Targeting gene virotherapy

Indexed keywords

BETA INTERFERON; ONCOLYTIC ADENOVIRUS; ONYX 015;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CELL LINE; CELL STRAIN HEK293; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HELA CELL; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR XENOGRAFT; VIRUS REPLICATION; VIRUS STRAIN;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; GENES, REPORTER; HUMANS; INTERFERON-BETA; LIVER NEOPLASMS; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; MUS MUSCULUS;

EID: 52649152367     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1231     Document Type: Article

References (41)

1. Vorburger SA, Hunt KK. Adenoviral gene therapy. The Oncologist 2002; 7: 46-59.
2. Kim D, Marruza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001; 7: 781-787.
3. Alemany R, Balagué C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000; 18: 723-727.
4. O'Shea CC, Johnson L, Bagus B, et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004; 6: 611-623.
5. Mulvihill S, Warren R, Venook A, et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 2001; 8: 308-315.
6. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-0151 an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 2000; 60: 6359-6366.
7. Makower D, Rozenblit A, Kaufman H, et al. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res 2003; 9: 693-702.
8. Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 2006; 98: 298-300.
9. Heise C, Sampson-Johannes A, Williams A, et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3: 639-645.
10. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885.
11. Bauzon M, Castro D, Karr M, Hawkins LK, Hermiston TW. Multigene expression from a replicating adenovirus using native viral promoters. Mol Ther 2003; 7: 526-534.
12. Hermiston TW, Kuhn I. Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther 2002; 9: 1022-1035.
13. Zou W, Luo C, Zhang Z, et al. A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene 2004; 23: 457-464.
14. Liu XY. Targeting gene-virotherapy of cancer and its prosperity. Cell Res 2006; 16: 879-886.
15. Liu XY, Gu JF. Targeting gene-virotherapy of cancer. Cell Res 2006; 16: 25-30.
16. Liu XY, Qiu SB, Zou WG, et al. Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5. Mol Ther 2005; 11: 531-541.
17. Pei Z, Chu L, Zou W, et al. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 2004; 39: 1371-1381.
18. Zhang Y, Gu J, Zhao L, et al. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy. Cancer Res 2006; 66: 4291-4298.
19. Zhao L, Gu J, Dong A, et al. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum Gene Ther 2005; 16: 845-858.
20. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-1421.
21. Jonasch E, Haluska FG. Interferon in oncologyical practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001; 6: 34-55.
22. Qin XQ, Tao N, Dergay A, et al. Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc Natl Acad Sci U S A 1998; 95: 14411-14416.
23. Wilderman MJ, Sun J, Jassar AS, et al. Intrapulmonary IFN-β gene therapy using an adenoviral vector is highly effective in a murine orthotopic model of bronchogenic adenocarcinoma of the lung. Cancer Res 2005; 65: 8379-8387.
24. Yoshida J, Mizuno M, Wakabayashi T. Interferon-β gene therapy for cancer: basic research to clinical application. Cancer Sci 2004; 95: 858-865.
25. Chawla-Sarkar M, Lindner DJ, Liu YF, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003; 8: 237-249.
26. Choi EA, Lei H, Maron DJ, et al. Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells. Cancer Res 2003; 63: 5299-5307.
27. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the anti-tumor effects of type I IFNs. J Exp Med 1999; 189: 1451-1460.
28. Chawla-Sarkar M, Leaman DW, Jacobs BS, Borden EC. IFN-β pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis. J Immunol 2002; 169: 847-855.
29. Liu S, Yu Y, Zhang M, Wang W, Cao X. The involvement of TNF-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-stimulated human dendritic cells to tumor cells. J Immunol 2002; 169: 847-855.
30. Leaman DW, Chawla-Sarkar M, Vyas K, et al. Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon stimulated gene that augments TRAIL/Apo2L-induced apoptosis. J Biol Chem 2002; 277: 28504-28511.
31. Odaka M, Wiewrodt R, DeLong P, et al. Analysis of the immunologic response generated by Ad.IFN during successful intraperitoneal tumor gene therapy. Mol Ther 2002; 6: 210-218.
32. Odaka M, Sterman DH, Wiewrodt R, et al. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon gene therapy is attributable to induction of systemic immunity. Cancer Res 2001; 61: 6201-6212.
33. Dong Z, Greene G, Pettaway C, et al. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta. Cancer Res 1999; 59: 872-879.
34. Kaynor C, Xin M, Wakefield J, Barsoum J, Qin XQ. Direct evidence that IFN-beta functions as a tumor-suppression protein. J Interferon Cytokine Res 2002; 22: 1089-1098.
35. Salmon P, Le Cotonnec JY, Galazka A, Abdul-Ahad A, Darragh A. Pharmacokinetics and pharmacodynamics of recombinant human interferon-b in healthy male volunteers. J Interferon Cytokine Res 1996; 16: 759-764.
36. Zhang ZL, Zou WG, Luo CX, et al. An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res 2003; 13: 481-489.
37. Zhang JF, Hu C, Geng Y, et al. Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy. Proc Natl Acad Sci U S A 1996; 93: 4513-4518.
38. Shashkova EV, Spencer JF, Wold WS, Doronin K. Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus. Mol Ther 2007; 15: 598-607.
39. Urosevic M, Fujii K, Calmels B, et al. Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas. J Clin Invest 2007; 117: 2834-2846.
40. Obuchi M, Fernandez M, Barber GN. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol 2003; 77: 8843-8856.
41. Kim DH, Wang Y, Le Boeuf F, Bell J, Thorne SH. Targeting of interferon-beta to produce a specific, multimechanistic oncolytic vaccinia virus. PLoS Med 2007; 4: e353.